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Abstract 
Pasteurella multocida toxin (PMT) is a potent mitogen for Swiss 3T3 fibroblasts and cytotoxic to embryonic bovine lung cells. Site-directed 
mutagenesis was used to investigate the functional signiticance of a three amino acid motif in PMT that is present in five other bacterial protein toxins 
which exhibit ADP-ribosyl transferase activity. Crude lysates of mutant clones were fully cytotoxic for embryonic bovine lung cells. Purified mutant 
toxin was also as effective at stimulating inositol phosphate turnover and nucleic acid synthesis as wild type toxin. We conclude that this motif has 
no functional signiticance in P~teurella multocida toxin. 
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1. In~~uction 
The osteolytic toxin of Pasteurella multocida (PMT), 
has been identified as a potent mitogen for cultured fi- 
broblasts [I]. PMT stimulates inositol phosphate accu- 
mulation, calcium mobilization [2], and phospho~lation 
by protein kinase C [3], and is mitogenic at picomolar 
concentrations [l]. It has also been shown to induce an- 
chorage independance in Rat1 cells [4]. Various lines of 
evidence suggest hat the toxin acts intracellularly, but 
the molecular mode of action of the toxin remains un- 
clear. 
A His-Glu-Trp amino acid motif has been identified 
in a number of bacterial protein toxins which exhibit 
ADP-ribosylation activity. The histidine residue is 
spaced 125 amino acids from the glutamic acid residue, 
which in turn precedes the t~ptophan residue by four 
amino acids [5]. Site-specific mutations of this putative 
ADP-ribosyl transferase motif have been used to attrib- 
ute functional significance to these amino acids in the 
case of Pseudomonas aeruginosa exotoxin A (ETA) [5,6]. 
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This was achieved primarily through the identification of 
His426 as a conformationally significant residue [7,5], and 
G1uss3 as an active site residue involved in NAD’ binding 
[S]. A structural model of ETA was used to locate His426 
within an a-helix in the carboxyl-terminal domain III of 
the enzyme [7], to which catalytic activity had been as- 
signed [9,10]. A range of His426 substitutions were used 
[6] to suggest hat this residue was crucial to the three 
dimensional structure of the catalytic site of ETA. 
In the case of diphtheria toxin (DT), photoaffinity 
labelling was used to locate GIu’~’ in an important cata- 
lytic region in DT [1 11, and subsequent substitution of 
G~u’~~ with aspartic acid reduced activity by at least 
lOO-fold [12]. 
In addition, the deletion of Glu14* has been shown to 
reduce DT activity considerably [13]. More recently, 
His*’ of DT has been linked with NAD+ binding [14,15]. 
This specific His-Glu-Trp motif occurs once in the 
PMT sequence, located towards the N-terminus [16]. 
Computer analysis of the amino acid sequence of PMT 
also located His29 in an a-helix, and predicted the peptide 
was likely to be flexible in this region (Ward P.N., un- 
published obse~ations). On this basis it seemed plausi- 
ble that similar functions might be assigned to this motif 
in PMT. 
We have investigated the potential role of the His-Glu- 
Trp motif in PMT, by making single and double muta- 
tions in this motif and testing for changes in the activity 
of the toxin. 
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2. Materials and methods 
2.1. Bacterial strains, plasmids and growth conditions 
Full length recombinant toxin is expressed from its own promoter in 
Escberichia coli hosts at much higher levels than that observed in P 
multocida, and for this reason all manipulations using infectious mate- 
rial were carried out under Category 3’ regulations as defined by the 
UK Advisory Committee for Genetic Manipulation (ACGM). 
E. coti strain XLl-Blue (Stratagene) was used as a general cloning 
host. E. co& strain GM242 (dam-) was used to isolate u~ethylat~ 
DNA for subsequent restriction enzyme digestion. E. coli strain CJ236 
(Boehringer) was used to produce uracil-rich single stranded (uss) DNA 
for use as a mutagenesis template as directed by the manufacturer. 
The full coding sequence of PMT was subcloned from pAJL13 [ 171, 
into pBluescript II SK- (Stratagene) and named pTox3. 
Culture of E.coli containing pTox3 derived clones was in L-broth 
[ 181, supplemented with ampiciUin at 5O,&ml and tetracycline at 10 pg/ 
ml, both from Sigma, with shaking at 37°C. 
2.2. Reagents 
Unless stated, all chemicals were from BDH. DNA modifying en- 
zymes were purchased from Boehringer Mannheim and used in accord- 
ance with the manufacturer’s instructions. Sequence determination of 
mutants was performed on single stranded (ss) template DNA using a 
Sequenase Version 2.0 kit (USB} in accordance with the instructions 
supplied. 
2.3. DNA preparation 
Plasmid DNA was isolated by alkaline lysis 1181. Single stranded 
DNA was prepared from XLl-Blue and CJ236 hosts transformed with 
pTox3 or its derivatives, using the VCSM13 helper bacteriophage 
(Stratagene), according to the man~acturer’s ins~ctions. 
2.4. Mutagenesis 
Oligonucleotide-directed mutagenesis of His*’ (H29) was carried out 
using sense strand wild type ss-template DNA, following the protocol 
supplied by Stratagene. The products of the mutagenesis reactions were 
transformed into E. coli strain GM242 (dam-) and plasmid DNA 
isolated for screening by restriction enzyme digestion with BcR 
(B~h~nger). H29 mutant clones were identified by the loss of the BclI 
recognition sequence at Hi?, and the mutation was verified by DNA 
sequencing. 
A site-directed mutagenesis procedure [19,20] was adopted to make 
GIu’~~ (E155) mutants, and the candidate clones screened by DNA 
sequencing. 
The oligonucleotide used for in vitro mutagenesis of His2’ to alanine 
(S~~~~GTCA~AGCATCAGTACAC~TC~ contained two 
base changes (underlined), whereas the oligonucleotides used to mutate 
GIu’~’ to alanine (S-dGGTTATATsTGGACCAT), and GIu’~~ to 
aspartic acid (5’-dGGGTTATA&TCTGGACC) contained single base 
changes (underlined). 
2.5. Toxin purification 
The initial stages of toxin purification were performed at ACGM 
category 3‘ where po~ntially infectious material was being handled. 
Later stages of the procedure were performed within a Class II biolog- 
ical safety cabinet. 
Wild type and mutant toxin was prepared using an adaptation of a 
previously published method [21]. Overnight cultures (800 ml) were 
grown as described above. Cell pellets were resuspended in 150 ml lysis 
buffer (5 mM EDTA, 50 mM T&-Cl (pH 7.2), 100 mM NaCl, 0.1% 
toluene and SO&ml lysozyme}, and incubated without stirring at room 
temperature for 2 h. The lysate was cleared by ~n~fugation at 
1,000 x g for 20 mitt, and nucleic acid removed by addition of DNase 
I and RNase A (both from Sigma) each to final concentrations of 10 
,@nl with incubation at 37°C for 1 h. The cleared lysate was filtered 
through 0.22pm hlters (Schleicher and Schuell) and protease inhibitors 
benzamidine and phenylmethylsulphonylfiuoride (Sigma) were added 
to final concentrations of 1 mM and 0.1 mM, respectively. The filtrate 
was fractionated by DEAE-~phacel (Pha~acia) chromato~aphy and 
preparative polyacrylamide gel electrophoresis as previously described 
(211. Protein concentration was estimated using the Pierce BCA protein 
assay kit. 
Cleared crude cell lysates were prepared from the mutant clones 
using a modified version of the purification procedure described. Five 
millili~e bacterial cultures were resuspended in2 ml of lysis btier with 
the addition of DNase I and RNase A, each to final concentrations of 
2O,&nl, with incubation at room temperature for 30 min. Lysates were 
then filtered through 0.22 pm filters (Schleicher and Schuell). 
Glycerol was added to samples of crude lysate and purified toxin to 
a final concentration of 50% before storage at -20°C. 
2.6. Embryonic bovine bmg (EBL) cell assay 
The cytotoxicity of toxin prepa~tions was assessed on standard 
96well microtitre plates using a previously published method [22], with 
the following modifications. 10 ~1 of cleared crude cell lysate was 
serially diluted ten-fold with 90 ~1 Eagle’s minimum essential medium 
(Flow), containing 10% fetal calf serum, and 90 ~1 of a suspension of 
EBL cells at 3 x lO’/ml added to each well. 
2.7. Swiss 3T3 ~robl~t assays 
Incorporation of [3H]th~~ne into DNA was assessed [23]. Conflu- 
ent, quiescent cultures of Swiss 3T3 cells were washed and incubated 
at 37°C in 2 ml of Dulbecco’s modified Eagles medium @MEM)/ 
Waymouths medium 1:l (v/v) containing 1 ,&i of [‘Hlthymidine per ml 
and various concentrations of rPMT or mutants of rPMT. After 40 h 
DNA synthesis was assessed by measuring the level of [Hlthymidine 
incorporated into the acid precipitable material. 
The ability of toxin preparations to stimulate inositol phosphate 
production was determined [2]. Confluent quiescent cultures of Swiss 
3T3 cells in 30 mm dishes were prelabeled with lo&i/ml [Z3H]inositol 
for 16-18 h. rPMT mutant toxin preparations were then added at a 
concentration of 10 ns/ml and the cultures were incubated at 37’C for 
4.5 h. LiCl was then added to a final concentration of 20 mM. After 
a further 30 min the reaction was terminated by replacing the medium 
with 1 ml of ice-cold HClO,. After 20 min at 4°C the extract was 
neutralized with 0.5 M KOH containing 25 mM HEPES, 5 mM EDTA, 
and 0.01% Phenol red. Precinitated KClO., was removed bv centrifuea- 
tion at 1,000 x g for 5 min. -Analysis of total inositol phosphates was 
by anion exchange chromatography. Samples were diluted to 10 ml with 
water and then loaded onto 1 ml of Dowex AGl-X8 (100-200 mesh, 
HCOO- form) in Bio-Rad Econo-columns. After washes with 3 x 10 ml 
of water and 2 x 10 ml of 60 mM NH&OOH, 5 mM Na,B,O, the 
inositol phosphate were eluted with 7 ml of 1 M NH,COGH, 0.1 M 
HCGOH. One millilitre of eluate was counted in 10 ml of Picofluor. 
3. Results 
3.1. O~igo~u~~eotide-directed ~~t~gene~~s 
The oligonucleotides used for in vitro mutagenesis 
were designed to substitute alanine for histidine at posi- 
tion 29 of PMT, and alanine or aspartic acid for the 
glutamic acid residue at position 155 of the toxin. The 
rationale for the substitution of alanine was to introduce 
a residue that was quite different in nature but consid- 
ered biochemically unreactive. The substitution of aspar- 
tic acid for glutamic acid was to maintain the character- 
istics of the side group while subtly altering the location 
of the charged moiety. Such a substitution has previously 
been shown to decrease the ADP-~bosyItr~sferase ac- 
tivity of diphtheria toxin by a factor of at least 100 [12]. 
A BclI restriction site encompassing His29 was lost by 
mutation and enabled rapid screening to be carried for 
the His29 to alanine mutation. One of ten randomly se- 
lected E. coli GM242 transformants from the His29 mut- 
agenesis reactions exhibited a different restriction endo- 
nuclease digestion pattern with Bcfl. The altered DNA 
fragment sizes were consistent with those expected fol- 
lowing the alteration of the BclI recognition sequence at 
amino acids 27-29, DNA sequence analysis corfinned 
that the desired His29 to alanine substitution had taken 
place. Since there was not a suitable restriction site at 
GlulS5, a more efficient mu~genesis trategy [19,20] was 
used to obtain mutations at this site. DNA isolated from 
pTox3 and pTox3/H29A was used to prepare uracil-rich 
template DNA for subsequent in vitro mutagenesis reac- 
tions. The improved efficiency of mutagenesis enabled 
candidate mutants to be screened directly by sequence 
analysis. The combination of single and double substitu- 
tions achieved using this technique are summarised in 
Table 1. 
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3.2. Properties of mutant PMT 
Toxin was purified from each of the mutant clones. 
Each toxin preparation behaved identically when sub- 
jected to anion exchange chromatography, or native 
PAGE and migrated to the same position on SDS- 
PAGE. 
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The eytopathic effect of crude lysates of the mutant 
clones was compared to that of the pTox3-wild type 
clone, using the EEL ceff assay. In all cases the prepara- 
tions of mutant toxin showed levels of cytotoxicity com- 
parable to that of wild-type toxin (Table 1). We ascribe 
the apparent increases of cytotoxicity observed in some 
cases to slight variations in the toxin content of crude 
lysates. 
Fig. 1, Dose response curves for the stimulation of DNA synthesis by 
rPMT or mutants of rPMT. Each point is the mean of two determina- 
tions and is expressed as a percentage of the incorporation given by 10% 
fetal bovine serum (27.3 x lo4 cpm). 
4. Discussion 
The ability of purified mutant toxins to initiate DNA 
synthesis in Swiss 3T3 fibroblasts was assessed (Fig. 1). 
There were no differences in either the relative potency 
of mutated toxins or their ability to stimulate DNA syn- 
thesis equivalent o that induced by 10% serum. Inositol 
phosphate acc~ulation was also measured. In all cases 
the purified mutant toxin prepa~tions exhibited compa- 
rable levels of activity to that of wild-type toxin (Fig. 2). 
Purified H29A mutant toxin also stimulated DNA syn- 
thesis and inositol phosphate turnover in similar 
amounts to that of wild type toxin (data not shown). 
Investigation of the mode of action of bacterial toxins 
has helped identify components of eukaryotic signal 
transduction pathways [24,25]. Severat of these toxins 
(notably pertussis toxin and cholera toxin) are known to 
modify G proteins [26,27]. Since p1 multocida toxin is 
mitogenic for cultured cells at extremely low concentra- 
tions it is likely to have an enzymatic mode of action on 
an as yet unidentified target. By analogy with other tox- 
ins it was tempting to speculate that its intracellular tar- 
get might be a G protein. Its role in stimulating inositof 
phosphate release would suggest hat the recently identi- 
fied Gq [28,29] could be a possible target, 
Table 1 
Site directed mutants of the His-Gfu-Trp motif and their EBL cytotox- 
icity 
Mutants His= EBL toxicity 
(end point 
dilution factor) 
We have shown that the His-Glu-Trp motif is not 
functional in PMT. Mutation of His29 to alanine did not 
affect any of the properties of PMT. Since the histidine 
residue in the motif is remote from the other two resi- 
dues, and PMT contains 18 additional histidine residues 
which might be functional, the GIu’~~ residue was also 
mutated either to alanine or to aspartic acid since a 
similar substitution has been shown to decrease the activ- 
ity of diphtheria toxin severely [121. The single and dou- 
ble mutants were fully active in inducing both eH]thy- 
midine incorporation and inositol phosphate accumula- 
tion. 
H29A Ala - - 
E155D - Asp - 
H29A E155D Aia Asp - 
HBA EXSSA Ala Ala - 
pTox3 (wt) - - - 
1.3 x IO’ 
1.0 x IO’ 
5.5 x 106 
1.3 x 10s 
5.5 x lob 
Combinations of point mutations were made in the rPMT gene as 
described in section 2. The cytotoxkity of crude lysate preparations of 
the mutant &ones was determined as described, and expressed as the 
mean of dupkate determinations of the cytotoxic end point dilution 
factor. 
This result is consistent with the failure to detect ADP- 
~bosylation using a novel method for the direct measure- 
ment of toxin-catalyzed ADP-~bosylatio~ using whole 
cells [30]. However, it was possible in view of the extreme 
potency of PMT that the cellular target was present at 
very low levels and could not be identified using this 
method. Our results make it unlikely that PMT has an 
ADP~~bosylating function. 
Sequence analysis of PMT shows no significant ho- 
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Fig. 2. rPMT mutants timulate inositol phosphate production in Swiss 
3T3 cells. Analysis of total inositol phosphates in rPMT and mutant 
rPMT treated Swiss 3T3 cells was as described in section 2. 
mology to either DNA or protein databases with the 
exception of Cytotoxic Necrotizing Factor 1 (CNFl) 
from Escherichia coli [31], which displays homology with 
the putative membrane associated central hydrophobic 
domain of PMT [16], but does not contain the His-Glu- 
Trp motif. The absence of any further similarities be- 
tween the PMT sequence and those in the databases is 
a further indication of the novelty of this molecule and 
of its mode of action. Recent experiments how that 
PMT potentiates stimulation of inositol phosphate by 
various mitogenic neuropeptides, which strongly sug- 
gests that PMT facilitates G protein coupling to 
phosphoinositol-phospholipase C [32]. The results pre- 
sented here suggest hat it is likely that PMT will have 
a novel molecular mode of action. 
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